Chargement en cours...
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
Studies focused on the killing of activated B-RAF melanoma cells by the histone deacetylase (HDAC) inhibitor AR42. Compared to other tumor cell lines, PDX melanoma isolates were significantly more sensitive to AR42-induced killing. AR42 and the multi-kinase inhibitor pazopanib interacted to activate...
Enregistré dans:
| Publié dans: | Oncotarget |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Impact Journals LLC
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5369969/ https://ncbi.nlm.nih.gov/pubmed/28146421 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14829 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|